Latest news with #moleculardiagnostics
Yahoo
2 days ago
- Business
- Yahoo
Kalorama Highlights Key Trends and Breakthroughs in Blood Typing Market in New Report
ARLINGTON, Va., June 27, 2025 /PRNewswire/ -- As the world of transfusion medicine evolves, so too does the complexity and capability of blood grouping and typing technologies. In its latest In-Vitro Diagnostics Business Outlook market analysis, Kalorama Information explores the shifting landscape of blood typing—from traditional methods to cutting-edge molecular diagnostics—and what it means for laboratories, vendors, and patients alike. The new article uncovers how automation and molecular innovations are transforming how laboratories identify blood types and manage transfusion compatibility. The study highlights how automated systems are becoming essential tools in labs facing staffing shortages, offering improved efficiency and reducing the risk of human error. The report also dives into the increasing role of molecular methods in resolving complex or rare blood group discrepancies—an area gaining urgency as the population of cancer patients and those requiring transfusions continues to grow. Perhaps most excitingly, Kalorama covers the discovery of a new blood group system, the first of its kind in five decades, which may carry serious implications for transfusion safety protocols and donor compatibility standards moving forward. Key report features include: The current and projected market size for blood grouping/typing technologies through 2029. A look at regional market leaders and growth trends in North America, Europe, and Asia Pacific. An overview of leading companies such as Grifols, QuidelOrtho, Bio-Rad, and others driving innovation in immunohematology. For industry stakeholders—from hospital labs to diagnostic OEMs—this report offers strategic insights into market dynamics, product innovation, and regional opportunities that are reshaping transfusion medicine. To learn more about the report or request access, visit or contact us at info@ About IVD Business Outlook In Vitro Diagnostics Business Outlook is a bimonthly publication from Kalorama Information, offering six issues annually—each dedicated to a distinct segment of the IVD industry. Designed for decision-makers across diagnostics and life sciences, the publication delivers exclusive market intelligence, including growth forecasts, market sizing, and share analysis. Each issue features in-depth coverage of diagnostic test categories, company profiles, mergers and acquisitions, regional trends, and expert analysis of key industry developments. With curated insights not found in mainstream sources, In Vitro Diagnostics Business Outlook is an essential resource for staying ahead in the global diagnostics market. About Kalorama InformationKalorama Information, a division of Science and Medicine Group, is a leading provider of healthcare market research, delivering actionable intelligence to diagnostics, biotechnology, medical device, and pharmaceutical companies worldwide. Media Contact:Name: Alisa AlvichTitle: Marketing DirectorEmail: marketing@ (703)778-3080Company: Kalorama Information, a Science and Medicine Group companyWebsite: View original content to download multimedia: SOURCE Kalorama Information Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Zawya
17-06-2025
- Business
- Zawya
Gulf Scientific Corporation announces strategic partnership with GeneMind Biosciences
DUBAI, United Arab Emirates: Gulf Scientific Corporation (GSC), a leading provider of scientific and laboratory solutions, is pleased to announce a strategic partnership with GeneMind Biosciences, a pioneering developer of DNA sequencing systems. This alliance marks a significant milestone in our ongoing commitment to delivering innovative healthcare solutions and advancing molecular diagnostics. Founded with a focus on research and development, GeneMind Biosciences is a key player in the development of high-performance DNA sequencers - core instruments of modern molecular diagnostics. The company is committed to building a comprehensive precision medical ecosystem by collaborating with genetic testing service providers and medical institutions worldwide. This partnership with GSC represents a shared vision to enhance diagnostic capabilities, support cutting-edge scientific research, and ultimately improve patient outcomes. By combining GSC's extensive network and expertise with GeneMind's innovative sequencing technology, we aim to drive forward the future of healthcare through advanced molecular diagnostics, including non-invasive prenatal testing (NIPT). GSC is proud to represent GeneMind Biosciences in the UAE, Kuwait, Oman, Bahrain, and Qatar, bringing their groundbreaking NIPT technology to healthcare providers and patients across these markets. GeneMind's cutting-edge NIPT technology allows for early and accurate detection of fetal chromosomal abnormalities, reducing the risk of miscarriage and improving pregnancy outcomes. This technology has the potential to revolutionize prenatal care and improve the lives of expectant mothers. "We are excited to collaborate with GeneMind Biosciences, whose innovative DNA sequencing solutions align perfectly with our mission to empower healthcare providers to achieve their scientific objectives by providing innovative and reliable solutions, application support, and comprehensive after-sales services," stated Manaf Afyouni, Managing Director of Gulf Scientific Corporation. "Our partnership will enable us to bring cutting-edge NIPT technology to the region, enhancing prenatal care and improving patient outcomes." As part of this strategic partnership, GSC will be providing comprehensive support and services to healthcare professionals within the region. This collaboration will also facilitate the development of new research initiatives and projects focused on advancing molecular diagnostics and NIPT. We look forward to sharing updates on the groundbreaking initiatives and projects that will result from this strategic partnership. For more information about Gulf Scientific Corporation and our solutions, including GeneMind's NIPT technology, please visit Source: AETOSWire Contact details: Manaf Afyouni Email: marketing@ Website:
Yahoo
17-06-2025
- Business
- Yahoo
SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and intends to carry out a directed share issue of approximately MSEK 30
STOCKHOLM, June 17, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced it has signed a collaboration and license agreement with Castle Biosciences (NASDAQ: CSTL), a US-based leader in molecular diagnostics. The initial goal of the collaboration is to develop a test that predicts flares in patients diagnosed with atopic dermatitis (AD). The method will be based on SciBase's EIS technology and specifically, Nevisense, inclusive of both the desktop and point-of care devices. In connection with the collaboration and license agreement, SciBase intends to carry out a directed share issue of approximately SEK 30 million, of which Castle Biosciences has undertaken to subscribe for shares corresponding to a total amount of approximately SEK 19 million. The subscription price in the directed share issue corresponds to SEK 0.40 per share. Additional information regarding the directed share issue will be announced through a separate press release in connection with this press release. Under the collaboration and license agreement, the Companies will jointly explore and develop various clinical indications related to dermatologic diseases. SciBase's initial territory will be the EU, Switzerland, United Arab Emirates, Japan and South Korea, while Castle Biosciences' initial territory will be North America. Assuming development success, SciBase will receive a single-digit royalty percentage on the Castle gross margin as well as a low double-digit percentage mark-up on product sales to Castle. SciBase will also receive a milestone payment of 5 million U.S. dollars when Castle sales reach 50 million U.S. dollars annually. While the development agreement calls for sharing of development costs, SciBase will be deferring its clinical development costs for the initial indication of pre-symptomatically predicting flares in patients diagnosed with atopic dermatitis, with reimbursement being made from future royalty and milestone payments. "This collaboration with Castle Biosciences is exciting for SciBase," said Pia Renaudin, CEO of SciBase. "It will accelerate the use of Nevisense within the skin barrier health market. It will rapidly broaden our already existing clinical studies pipeline by increasing the number of studies, ultimately speeding up access to more effective therapies for patients with skin barrier dysfunction. We are also pleased to welcome Castle as a shareholder in SciBase." "We are excited to expand our commitment to the dermatologic community, clinicians and patients alike, with the signing of this agreement," said Derek Maetzold, CEO of Castle Biosciences. "Atopic dermatitis is a disease that impacts a significant number of lives, worldwide. We are excited about this opportunity to work with SciBase to develop a test that could improve the management of patients diagnosed with this disease, and potentially other dermatologic diseases. We believe this is a good fit for us, with our existing commercial portfolio of tests in skin cancers, as well as our pipeline test in development for use in patients diagnosed with moderate-to-severe AD who are seeking systemic treatment - the majority of which are managed by the same dermatological clinician." In connection with the collaboration and license agreement, SciBase intends to carry out a directed share issue of approximately SEK 30 million. The subscription price in the directed share issue corresponds to SEK 0.40 per share. Castle Biosciences has undertaken to subscribe for 47,886,950 shares in the directed share issue, corresponding to approximately SEK 19 million. Through the directed share issue, Castle Biosciences is becoming one of SciBase's largest shareholders. Additional information regarding the directed share issue will be announced through a separate press release in connection with this press release and will be available at: About Skin Barrier Dysfunction Skin barrier dysfunction is a key contributing factor to a wide range of skin disorders - including atopic dermatitis, psoriasis, ichthyosis, rosacea, and even acne. Estimates suggest that over 500 million people globally are affected by conditions in which skin barrier impairment plays a central role. Estimated global prevalence by condition includes: Atopic dermatitis (eczema): ~223 million1) Psoriasis: ~125 million2) Rosacea: ~400 million (many with impaired barrier function)3) Additionally, a wide range of cosmetic and subclinical skin concerns-such as dryness, irritation, and product sensitivity-are linked to mild or temporary skin barrier disruption. These milder forms may affect over a billion people globally at some point in their lives. This information is information that SciBase Holding AB is obliged to make public pursuantto the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 22.30 CEST on June 16, 2025. About Castle BiosciencesCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. For further information please contact: Pia Renaudin, CEO,Phone. +46732069802E-mail: Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ)Tel: +46 (0)73 856 42 65E-mail: certifiedadviser@ About SciBase and NevisenseSciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at For press releases and financial reports visit: -------------------------------------------------------------------------------------- 1Global Report on Atopic Dermatitis - 2https:// 3https:// This information was brought to you by Cision The following files are available for download: SciBase PR - collaboration - final Nevisense Go Nevisense new software 2025 with curve EU View original content:
Globe and Mail
09-06-2025
- Business
- Globe and Mail
Molecular Infectious Disease Testing: A Strategic Imperative in the Next Era of Diagnostic Innovation
"Key players in the molecular infectious disease testing market include Danaher (US), F. Hoffmann- La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany)" The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 billion by 2029. Major drivers of market growth include rising burden of infectious diseases and rapid technological advancements in molecular diagnostics. In a world increasingly shaped by precision medicine and real-time response to public health threats, Molecular Infectious Disease Testing has emerged as a critical force driving both clinical excellence and strategic business transformation. As healthcare systems, diagnostic developers, and life sciences firms recalibrate in the wake of global disruptions, this once-specialized segment now anchors a new paradigm of proactive, data-driven, and resilient healthcare. The Molecular Infectious Disease Testing Market is poised for significant expansion—powered by evolving pathogen landscapes, digital diagnostics, and next-gen sample-to-answer platforms. For C-suite leaders, this moment presents a rare convergence of public health necessity, commercial scalability, and long-term strategic advantage. Download PDF Brochure: Reframing Diagnostics: From Passive Detection to Intelligent Surveillance Historically, infectious disease diagnostics operated as reactive tools—used to confirm a clinical suspicion. Today, molecular testing reframes this narrative. It offers early detection, predictive analytics, and pathogen-level precision across clinical, commercial, and community settings. From hospital labs to point-of-care environments, molecular diagnostics enable providers to shift from treatment to prevention, aligning with global healthcare imperatives. Molecular platforms—driven by PCR, isothermal amplification, and CRISPR-based innovations—now deliver results in under an hour with laboratory-grade accuracy. This speed-accuracy fusion is not merely a clinical upgrade; it fundamentally redefines operational models for diagnostic providers, healthcare systems, and public health authorities. For enterprises invested in diagnostics, the value proposition is clear: real-time infectious disease visibility fuels smarter resource allocation, reduces hospital burden, and enhances patient outcomes, all while positioning stakeholders as architects of the next diagnostic frontier. Strategic Growth Catalysts: What's Driving Market Acceleration Several macro and micro factors coalesce to propel the Molecular Infectious Disease Testing Market into its next growth phase: 1. Expanding Disease Burden and Antimicrobial Resistance (AMR) The global burden of infectious diseases remains persistent, with resurging pathogens (e.g., RSV, TB, dengue) and emerging zoonotic threats challenging static diagnostic infrastructure. Molecular tools provide the agility and specificity needed to differentiate bacterial from viral infections, a critical step in curbing unnecessary antibiotic use and mitigating AMR. 2. Decentralization of Diagnostics The COVID-19 era taught healthcare an invaluable lesson: decentralization saves lives. With the rise of near-patient and at-home molecular testing platforms, diagnostics are no longer tethered to centralized labs. Enterprises that adapt their go-to-market strategies to support distributed testing architectures —via partnerships with retail clinics, mobile labs, or remote monitoring—will unlock new access points and patient touchpoints. 3. Integration with Digital Health and AI AI and machine learning now bolster molecular diagnostics by enhancing pathogen detection accuracy, analyzing multi-pathogen panels, and predicting outbreak trajectories. Diagnostic systems integrated with EHRs and cloud platforms empower real-time clinical decisions, operational benchmarking, and population-level insights. This digital-molecular fusion presents fertile ground for healthcare innovation. 4. Policy and Funding Momentum Across North America, Europe, and APAC, health authorities are expanding reimbursement codes, issuing preparedness grants, and incentivizing rapid diagnostics in low-resource and high-risk settings. This public-private alignment creates a robust financial scaffold that enables enterprise-level scaling of molecular platforms. Real-World Applications: Impact Across Ecosystems Molecular infectious disease testing is already reshaping operations in high-stakes environments: - Hospitals and Health Systems Rapid syndromic panels reduce patient length of stay, enhance cohorting strategies, and improve antimicrobial stewardship. Molecular diagnostics empower ID specialists to tailor therapy within hours, leading to better outcomes and lower costs per diagnosis. - Pharmaceutical R&D Clinical trial timelines for anti-infectives depend on early, accurate identification of pathogens. Molecular testing accelerates patient enrollment and pathogen profiling, de-risking development pipelines and expediting time-to-market for novel therapeutics. - Public Health and Biosecurity Central and regional agencies are embedding molecular testing into surveillance systems. These platforms offer real-time outbreak detection and genomic surveillance to preempt community spread, identify variants, and inform containment protocols. - Travel, Defense, and Corporate Health Airports, military bases, and corporate campuses now deploy rapid molecular testing for pre-entry screening and ongoing surveillance. This enables safe continuity of operations in mission-critical sectors. Industry Trends and Long-Term Shifts: Preparing for 2030 The next five years will define the blueprint for molecular diagnostics—shaped by three dominant themes: 1. Platform Convergence The future is not single-pathogen but multiplexed and modular. Next-gen systems will support simultaneous detection of viral, bacterial, and fungal targets on customizable panels—driven by cloud-based upgrades and modular chemistry. 2. Global Accessibility Low- and middle-income countries (LMICs) represent a major growth frontier. Companies investing in affordable, ruggedized, solar-compatible molecular platforms stand to gain first-mover advantage in these underserved yet high-need markets. 3. Consumerization and At-Home Testing With rising health literacy and demand for convenience, molecular diagnostics will continue migrating into consumer channels, supported by e-commerce, telehealth integration, and mobile sample logistics. Strategic partnerships with digital health platforms will be crucial for brand relevance and scale. Business Opportunity Landscape: Where the Growth Lies C-suite leaders, investors, and business strategists eyeing the molecular infectious disease testing space should consider five high-potential opportunity zones: A. Horizontal Expansion into Adjacent Conditions Beyond traditional infectious diseases, molecular platforms are being adapted for oncology (viral-driven cancers), transplant monitoring, and immune dysfunction diagnostics. This expands addressable markets and strengthens platform utility. B. Strategic M&A and Licensing Models Smaller diagnostic innovators with novel amplification chemistries, miniaturized hardware, or AI overlays are ripe for acquisition or joint ventures. Corporates seeking to build comprehensive diagnostic ecosystems must prioritize these integrations. C. Private-Public Lab Collaborations Innovative partnerships between diagnostics firms and health agencies (local, federal, or international) will streamline test deployment in underserved geographies, leveraging pooled resources and shared logistics. D. Outcome-Based Reimbursement Models The shift to value-based care compels diagnostics providers to demonstrate impact on outcomes and cost avoidance. Firms that can link molecular testing to reduced admissions, antibiotic usage, or outbreak costs will command premium reimbursements. E. Supply Chain and Manufacturing Localization Post-pandemic disruptions underscore the value of regionalized manufacturing and agile logistics. Companies investing in decentralized, scalable production will enjoy lower lead times, geopolitical risk insulation, and margin protection. A Call to Action: Redefining the Diagnostic Future The evolution of Molecular Infectious Disease Testing represents more than a technological upgrade—it's a business imperative with the potential to redefine diagnostics, reshape public health response, and reimagine the value chain across healthcare. Senior executives who treat molecular testing as a strategic pillar—not a supplemental tool—will lead the industry's transformation. This moment requires bold investments, long-horizon vision, and operational agility. Whether you are a diagnostic innovator, a health system leader, a policy architect, or a life sciences strategist, the time to act is now. The trajectory is clear: the future of infectious disease testing is molecular, digital, decentralized, and intelligent. Those who move early, scale smartly, and innovate continuously will not only lead markets—they will help safeguard global health. For more information, Inquire Now!
Entrepreneur
07-06-2025
- Business
- Entrepreneur
Biopeak Raises USD 3.5 Million to Expand AI-Driven Health Clinics
"We're at a unique point where developments in molecular diagnostics, AI, and imaging allow us to understand the human body in unprecedented ways," says Rishi Pardal, Co-founder and CEO of Biopeak Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Biopeak, a wellness and longevity-focused startup headquartered in Bengaluru, has raised USD 3.5 million (approximately INR 29 crore) in seed funding from a group of notable investors. The round saw participation from Accel founding partner Prashanth Prakash, Claypond Capital--the family office of Manipal Group chairman Ranjan Pai and NKSquared, the investment arm of Zerodha co-founder Nikhil Kamath. Founded in 2024 by Rishi Pardal and Shiva Subramanian, Biopeak delivers personalised health services through its own clinics, combining advanced diagnostics, molecular science, and artificial intelligence (AI) to monitor early signs of physiological change. The company launched its first clinic in Bengaluru in March 2025. The funding will be used to expand Biopeak's clinic footprint across key Indian cities and strengthen its AI-based diagnostic and care delivery platform. "We're at a unique point where developments in molecular diagnostics, AI, and imaging allow us to understand the human body in unprecedented ways," said Rishi Pardal, Co-founder and CEO of Biopeak. "Our platform translates these insights into actionable, individualised health plans aimed at extending one's healthspan, not just lifespan." Biopeak's approach includes a suite of diagnostic tools such as microbiome mapping, organic acid profiling, salivary cortisol rhythm analysis, and whole-exome functional genomics. These are integrated with non-invasive imaging technologies including MRI, CT, DXA, and ECHO, along with tissue-level screenings to assess toxin levels, mineral balance, and oxidative stress. Clients typically undergo more than six hours of detailed consultations guided by a dedicated health manager and a multidisciplinary team of specialists. Health plans are updated regularly based on follow-up tests and consultations. Commenting on the investment, Prashanth Prakash said, "As India's population ages, our challenge is to build systems that not only extend life but also improve the quality of those extended years. Geroscience, early interventions, and scalable healthcare models will be central to this shift." Prakash, who also mentors Biopeak, is the Founding Patron of Longevity India, a platform focused on ageing research and interventions tailored for India's demographic needs.
